The ubiquitin system for intracellular protein degradation - Involvement in human pathologies and therapeutic implications

Harefuah

Volumn 143, Issue 8, 2004, Pages

  Reinstein, Eyal ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Cancer; Inflammation; Proteasome inhibitors; Protein degradation; Ubiquitin

Indexed keywords

BORTEZOMIB; LACTACYSTIN BETA LACTONE; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN;

ARTERY OCCLUSION; ASTHMA; CELL CYCLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; GENE EXPRESSION; HUMAN; INFLAMMATION; MULTIPLE MYELOMA; NONHUMAN; PROTEIN DEGRADATION; RHEUMATOID ARTHRITIS; SHORT SURVEY;

DISEASE; HUMANS; PATHOLOGY; PROTEINS; UBIQUITIN;

EID: 19244365362     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (18)

1. Glickman MH & Ciechanover A, The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev, 2002; 82: 373-428.
2. Sakamato MK, Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies. Mol Genet Metab, 2002; 77: 44-56.
3. McGrath JP, Jentsch S & Varshavsky A, UBA1: an essential yeast gene encoding ubiquitin-activating enzyme. EMBO J, 1991; 10: 227-236.
4. Matsuura T, Sutcliffe JS, Fang P & al, De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet, 1997; 15: 74-77.
5. Abriel H, Loffing J, Rebhun JF & al, Defective regulation of the epithelial Na channel by Nedd4 in Liddle's syndrome. J Clin Invest, 1999; 103: 667-673.
6. Scheffner M, Huibregtse JM, Vierstra RD & al, The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell, 1993; 75: 495-505.
7. Scheffner M & Whitaker NJ, Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol, 2003; 13: 59-67.
8. Wong BR, Parlati F, Qu K & al, Drug discovery in the ubiquitin regulatory pathway. Drug Discov Today, 2003; 8: 746-754.
9. Elliott PJ, Zollner TM & Boehncke WH, Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med, 2003; 81: 235-245.
10. Richardson PG, Barlogie B, Berenson J & al, A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 2003; 348: 2609-2617.
11. Aghajanian C, Soignet S, Dizon DS & al, A phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies. Clin Cancer Res, 2002; 8: 2505-2511.
12. Meiners S, Laule M, Rother W & al, Ubiquitin proteasome pathway as a new target for the prevention of restenosis. Circulation, 2002; 105: 483-489.
13. Yeh TH, Ubiquitin, proteasome and restenosis. Circulation, 2002; 105: 408-410.
14. Elliott PJ, Pien CS, McCormack TA & al, Proteasome inhibition: a novel mechanism to combat asthma. J Allergy Clin Immunol, 1999; 104; 294-300.
15. Cromartie WJ, Craddock JC, Schwab JH & al, Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med, 1977; 146: 1585-1602.
16. Palombella VJ, Conner EM, Fuseler JW & al, Role of the proteasome and NF-kappa B in streptococcal cell-wall induced polyarthritis. Proc Natl Acad Sci (USA), 1998; 95: 15671-15676.
17. Phillips JB, Williams AJ, Adams J al, Proteasome inhibitor PS-519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke, 2000; 31: 1686-1693.
18. Zhang L, Zhang ZG, Zhang RL al, Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke, 2001; 32: 2926-2931.